🔗 Share this article

A shadow economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, based on recent findings.

Investigational Drug Gaining Popularity Via Social Media

The experimental drug, which is still in research studies, is being advertised by social media influencers for its alleged fat-burning effects. Viewers are encouraged to contact these profiles directly for source information, while also receiving discount codes.

Active Trade on Messaging Platforms

Separately, a flourishing market exists on Telegram, where communities with thousands of participants share comparison images, administration instructions and assertions of next-day UK delivery. Sellers promote the drug there before directing buyers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the next Ozempic.

Medical Experts Express Worries

However, doctors and pharmacists have warned that the sale of what is still an unapproved medication in the United Kingdom is a cause for concern and could result in individuals injecting substances of unknown origin.

Some professionals said the popularity for retatrutide could be connected to the rising cost of approved weight loss products such as Mounjaro.

Legal Position and Enforcement

Selling the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and supply can still breach medicines, advertising, and customer regulations, potentially leading to penalties, legal action or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the platform has removed violative material and banned related hashtags and query recommendations. The company said it was committed to maintaining the service secure and investing in enhancing compliance measures.

Online Marketplace Operations

Research also discovered groups with up to 9,000 members selling the experimental drug using the platform's built-in discovery tool, which functions like a online catalog. Typing “retatrutide” immediately displays groups with numerous of users, filled with photos of weight loss, positive testimonials and step-by-step guides for mixing or administering at residence.

After minutes of entering one community, a seller posted WhatsApp details, where the majority of purchases take place. The vendor provided an instruction manual and guaranteed shipping within two days. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one asked about weight, medical conditions or past usage.

Product Information and Costs

Within these groups, posts display black plastic packages with postal service labels, stating to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at residence with sterile water, or pre-filled injectors usually sold at 160 pounds for 20 milligrams. When asked how much time a injector should be used, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for the messaging service said it actively moderated dangerous material on its platform including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are administering materials they can’t verify. Even if the science behind retatrutide is valid, these online products may not include what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor connected the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are using online platforms. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.

Her team has already seen individuals harmed by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” stated Wyllie. “These substances could be impure or incorrectly dosed.”

Manufacturer Position

A spokesperson from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this point no one can market [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company experimental product not yet approved … may subject users to possibly serious health risks”.